{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Dyslipidemia", "Lipid regulating agents", "Metastasis", "Statins", "Tumor"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38015371", "DateCompleted": {"Year": "2024", "Month": "02", "Day": "02"}, "DateRevised": {"Year": "2024", "Month": "02", "Day": "06"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "11", "Day": "28"}], "Language": ["eng"], "ELocationID": ["10.1007/s43440-023-00553-6"], "Journal": {"ISSN": "2299-5684", "JournalIssue": {"Volume": "76", "Issue": "1", "PubDate": {"Year": "2024", "Month": "Feb"}}, "Title": "Pharmacological reports : PR", "ISOAbbreviation": "Pharmacol Rep"}, "ArticleTitle": "Lipid-lowering drugs and cancer: an updated perspective.", "Pagination": {"StartPage": "1", "EndPage": "24", "MedlinePgn": "1-24"}, "Abstract": {"AbstractText": ["Statins and non-statin medications used for the management of dyslipidemia have been shown to possess antitumor properties. Since the use of these drugs has steadily increased over the past decades, more knowledge is required about their relationship with cancer. Lipid-lowering agents are heterogeneous compounds; therefore, it remains to be revealed whether anticancer potential is a class effect or related to them all. Here, we reviewed the literature on the influence of lipid-lowering medications on various types of cancer during development or metastasis. We also elaborated on the underlying mechanisms associated with the anticancer effects of antihyperlipidemic agents by linking the reported in vivo and in vitro studies."], "CopyrightInformation": "\u00a9 2023. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Echocardiography Research CenterRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Alizadehasl", "ForeName": "Azin", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Echocardiography Research CenterRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Alavi", "ForeName": "Maryam Sadat", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Echocardiography Research CenterRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Boudagh", "ForeName": "Shabnam", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Alavi", "ForeName": "Mohaddeseh Sadat", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Echocardiography Research CenterRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Mohebi", "ForeName": "Somaye", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Echocardiography Research CenterRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Aliabadi", "ForeName": "Leila", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Echocardiography Research CenterRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Akbarian", "ForeName": "Mahsa", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Echocardiography Research CenterRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran."}], "LastName": "Ahmadi", "ForeName": "Parisa", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine and Surgery, University of Perugia, Perugia, Italy."}], "LastName": "Mannarino", "ForeName": "Massimo R", "Initials": "MR"}, {"Identifier": ["0000-0002-8656-1444"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. amir_saheb2000@yahoo.com."}, {"Identifier": [], "Affiliation": "Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. amir_saheb2000@yahoo.com."}], "LastName": "Sahebkar", "ForeName": "Amirhossein", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmacol Rep", "NlmUniqueID": "101234999", "ISSNLinking": "1734-1140"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Hypolipidemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Lipids"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Hypolipidemic Agents"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Dyslipidemias"}, {"QualifierName": ["drug therapy", "complications"], "DescriptorName": "Neoplasms"}, {"QualifierName": [], "DescriptorName": "Lipids"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778\u201389.", "ArticleIdList": ["10.1002/ijc.33588"]}, {"Citation": "Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, Hashemi S-M, Balouchi A. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;176:519\u201333.", "ArticleIdList": ["31087199", "10.1007/s10549-019-05271-3"]}, {"Citation": "Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Global Health. 2019;9:217.", "ArticleIdList": ["10.2991/jegh.k.191008.001"]}, {"Citation": "Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14:85.", "ArticleIdList": ["34059100", "8165984", "10.1186/s13045-021-01096-0"]}, {"Citation": "Luo J, Yang H, Song B-L. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225\u201345.", "ArticleIdList": ["31848472", "10.1038/s41580-019-0190-7"]}, {"Citation": "Riscal R, Skuli N, Simon MC. Even cancer cells watch their cholesterol! Mol Cell. 2019;76:220\u201331.", "ArticleIdList": ["31586545", "7225778", "10.1016/j.molcel.2019.09.008"]}, {"Citation": "Vona R, Iessi E, Matarrese P. Role of cholesterol and lipid rafts in cancer signaling: a promising therapeutic opportunity? Front Cell Dev Biol. 2021;9: 622908.", "ArticleIdList": ["33816471", "8017202", "10.3389/fcell.2021.622908"]}, {"Citation": "Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, et al. Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals. 2022;15:151.", "ArticleIdList": ["35215263", "8877351", "10.3390/ph15020151"]}, {"Citation": "Maqsood MH, Messerli FH, Waters D, Skolnick AH, Maron DJ, Bangalore S. Timing of statin dose: a systematic review and meta-analysis of randomized clinical trials. Eur J Prev Cardiol. 2022;29:e319\u201322.", "ArticleIdList": ["35512427", "10.1093/eurjpc/zwac085"]}, {"Citation": "Mayengbam SS, Singh A, Pillai AD, Bhat MK. Influence of cholesterol on cancer progression and therapy. Transl Oncol. 2021;14: 101043.", "ArticleIdList": ["33751965", "8010885", "10.1016/j.tranon.2021.101043"]}, {"Citation": "Yang J, Wang L, Jia R. Role of de novo cholesterol synthesis enzymes in cancer. J Cancer. 2020;11:1761\u20137.", "ArticleIdList": ["32194787", "7052851", "10.7150/jca.38598"]}, {"Citation": "Hassanabad AF. Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Transl Lung Cancer Res. 2019;8:692.", "ArticleIdList": ["10.21037/tlcr.2019.09.08"]}, {"Citation": "Pedersen TR. Lipid-lowering drugs and risk for cancer. Curr Atheroscler Rep. 2009;11:350\u20137.", "ArticleIdList": ["19664378", "10.1007/s11883-009-0053-3"]}, {"Citation": "Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35:1082\u201398.", "ArticleIdList": ["23932550", "10.1016/j.clinthera.2013.06.019"]}, {"Citation": "Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect? Cardiovasc Drugs Ther. 2013;27:559\u201367.", "ArticleIdList": ["23913122", "10.1007/s10557-013-6479-4"]}, {"Citation": "Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbu\u015b K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17:1447\u2013547.", "ArticleIdList": ["34900032", "8641518", "10.5114/aoms/141941"]}, {"Citation": "Banach M, Reiner Z, Cicero AFG, Sabouret P, Viigimaa M, Sahebkar A, et al. 2022: The year in cardiovascular disease\u2014the year of upfront lipid lowering combination therapy. Arch Med Sci. 2022;18:1429\u201334.", "ArticleIdList": ["36457968", "9710261"]}, {"Citation": "Khonsary SA. Goodman and Gilman\u2019s the pharmacological basis of therapeutics. Surg Neurol Int. 2023;14:91.", "ArticleIdList": ["10070253", "10.25259/SNI_184_2023"]}, {"Citation": "Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230\u20138.", "ArticleIdList": ["30120976", "10.1016/j.phrs.2018.08.014"]}, {"Citation": "Chru\u015bciel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194\u2013208.", "ArticleIdList": ["27498397", "10.1016/j.atherosclerosis.2016.07.897"]}, {"Citation": "Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res. 2015;60:50\u201373.", "ArticleIdList": ["26416579", "10.1016/j.plipres.2015.08.003"]}, {"Citation": "Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60:175\u201399.", "ArticleIdList": ["32378144", "10.1007/s12016-020-08791-9"]}, {"Citation": "Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GYH, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015. https://doi.org/10.1038/srep09902 .", "ArticleIdList": ["10.1038/srep09902", "25970700", "4429557"]}, {"Citation": "Sohrevardi SM, Nasab FS, Mirjalili MR, Bagherniya M, Tafti AD, Jarrahzadeh MH, et al. Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Arch Med Sci. 2021;17:1423.", "ArticleIdList": ["34522273", "10.5114/aoms.2019.89330"]}, {"Citation": "Sahebkar A, Serban C, Mikhailidis DP, et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015;114(3):546\u201357. https://doi.org/10.1160/TH14-11-0937", "ArticleIdList": ["10.1160/TH14-11-0937", "26017749"]}, {"Citation": "Vahedian-Azimi A, Mohammadi SM, Beni FH, Banach M, Guest PC, Jamialahmadi T, et al. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch Med Sci. 2021;17:579\u201395.", "ArticleIdList": ["34025827", "8130467", "10.5114/aoms/132950"]}, {"Citation": "Gorabi AM, Kiaie N, Pirro M, Bianconi V, Jamialahmadi T, Sahebkar A. Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications. Heart Fail Rev. 2021;26:1259\u201372.", "ArticleIdList": ["32008148", "10.1007/s10741-020-09929-9"]}, {"Citation": "Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, et al. Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm. 2022. https://doi.org/10.1155/2022/8732360 .", "ArticleIdList": ["10.1155/2022/8732360", "35125965", "8816584"]}, {"Citation": "Bland AR, Payne FM, Ashton JC, Jamialahmadi T, Sahebkar A. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res. 2022;175: 105986.", "ArticleIdList": ["34800627", "10.1016/j.phrs.2021.105986"]}, {"Citation": "Sahebkar A, Serban C, Ursoniu S, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(3):520\u201332. https://doi.org/10.1160/TH15-08-0620", "ArticleIdList": ["26632869", "10.1160/th15-08-0620"]}, {"Citation": "Vahedian-Azimi A, Mannarino MR, Shojaie S, Rahimibashar F, Galeh HEG, Banach M, et al. Effect of statins on prevalence and mortality of influenza virus infection: a systematic review and meta-analysis. Arch Med Sci. 2022;18(6):1\u201344.", "ArticleIdList": ["10.5114/aoms/149633"]}, {"Citation": "Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, et al. Statin therapy and plasma coenzyme Q10 concentrations\u2014a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329\u201336.", "ArticleIdList": ["26192349", "10.1016/j.phrs.2015.07.008"]}, {"Citation": "Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-Analysis. Eur Heart J. 2022;43:3213\u201323.", "ArticleIdList": ["35169843", "9757867", "10.1093/eurheartj/ehac015"]}, {"Citation": "Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124:328\u201350.", "ArticleIdList": ["30653440", "10.1161/CIRCRESAHA.118.312782"]}, {"Citation": "Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? Front Cardiovasc Med. 2021;8: 687585.", "ArticleIdList": ["34095267", "8172607", "10.3389/fcvm.2021.687585"]}, {"Citation": "Afshari AR, Mollazadeh H, Henney NC, Jamialahmad T, Sahebkar A. Effects of statins on brain tumors: a review. Semin cancer biol. Elsevier; 2021. p. 116\u201333."}, {"Citation": "Beckwitt CH, Brufsky A, Oltvai ZN, Wells A. Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Res. 2018;20:144.", "ArticleIdList": ["30458856", "6247616", "10.1186/s13058-018-1066-z"]}, {"Citation": "Cruz PM, Mo H, McConathy WJ, Sabnis N, Lacko AG. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol. 2013;4:119.", "ArticleIdList": ["24093019", "3782849", "10.3389/fphar.2013.00119"]}, {"Citation": "Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:1\u201319.", "ArticleIdList": ["10.1155/2014/149185"]}, {"Citation": "Amin F, Fathi F, Reiner \u017d, Banach M, Sahebkar A. The role of statins in lung cancer. Arch Med Sci. 2022;18:141\u201352.", "ArticleIdList": ["35154535"]}, {"Citation": "Grabarek BO, Boro\u0144 D, Morawiec E, Michalski P, Palazzo-Michalska V, Pach \u0141, et al. Crosstalk between statins and cancer prevention and therapy: an update. Pharmaceuticals (Basel, Switzerland). 2021;14:1220.", "ArticleIdList": ["34959621", "10.3390/ph14121220"]}, {"Citation": "Shi M, Zheng H, Nie B, Gong W, Cui X. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open. 2014;4: e005399.", "ArticleIdList": ["25227628", "4166249", "10.1136/bmjopen-2014-005399"]}, {"Citation": "Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2013;368:576\u20137.", "ArticleIdList": ["23388012"]}, {"Citation": "Tuyet Kristensen D, Kisbye \u00d8vlisen A, Hjort Kyneb Jakobsen L, Tang Severinsen M, Hannig LH, Starklint J, et al. Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study. Blood Adv. 2023;7:3450\u20137.", "ArticleIdList": ["36877642", "10362262", "10.1182/bloodadvances.2023009784"]}, {"Citation": "Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN. Long-term use of statins and risk of colorectal cancer: a population-based study. ACG. 2009;104:3015\u201323."}, {"Citation": "Wang J, Li C, Tao H, Cheng Y, Han L, Li X, et al. Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials. PLoS\u00a0One. 2013;8: e77950.", "ArticleIdList": ["24205041", "3808274", "10.1371/journal.pone.0077950"]}, {"Citation": "Babcook MA, Joshi A, Montellano JA, Shankar E, Gupta S. Statin use in prostate cancer: an update. Nutr Metab Insights. 2016;9:S38362.", "ArticleIdList": ["10.4137/NMI.S38362"]}, {"Citation": "Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014;15:461\u20138.", "ArticleIdList": ["10.1016/S1470-2045(14)70119-6"]}, {"Citation": "Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England). 2012;380:581\u201390.", "ArticleIdList": ["22607822", "10.1016/S0140-6736(12)60367-5"]}, {"Citation": "Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank. Elife. 2020;9: e57191.", "ArticleIdList": ["33046214", "7553780", "10.7554/eLife.57191"]}, {"Citation": "Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409\u201318.", "ArticleIdList": ["17662392", "10.1016/j.jacc.2007.02.073"]}, {"Citation": "Hoffmann P, Roumegu\u00e8re T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med. 2006;355:2705\u20137.", "ArticleIdList": ["17183004", "10.1056/NEJMc062714"]}, {"Citation": "Symvoulidis P, Tsioutis C, Zamboglou C, Agouridis AP. The effect of statins on the incidence and prognosis of bladder cancer: a systematic review and meta-analysis. Curr Oncol. 2023;30:6648\u201365.", "ArticleIdList": ["37504348", "10378493", "10.3390/curroncol30070488"]}, {"Citation": "Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461\u20138.", "ArticleIdList": ["21813413", "3186780", "10.1093/jnci/djr291"]}, {"Citation": "Liu B, Yi Z, Guan X, Zeng YX, Ma F. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Res Treat. 2017;164:1\u201311.", "ArticleIdList": ["28432513", "10.1007/s10549-017-4246-0"]}, {"Citation": "Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. Statin use and breast cancer survival: a nationwide cohort study from Finland. PLoS\u00a0One. 2014;9: e110231.", "ArticleIdList": ["25329299", "4203770", "10.1371/journal.pone.0110231"]}, {"Citation": "Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology. 2015;26:68\u201378.", "ArticleIdList": ["25304447", "10.1097/EDE.0000000000000189"]}, {"Citation": "Mc Menamin \u00daC, Murray LJ, Hughes CM, Cardwell CR. Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer. 2016;16:600.", "ArticleIdList": ["27491389", "4973520", "10.1186/s12885-016-2651-0"]}, {"Citation": "Jalving M, Koornstra J, De Jong S, De Vries E, Kleibeuker J. the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther. 2005;21:321\u201339.", "ArticleIdList": ["15709983", "10.1111/j.1365-2036.2005.02335.x"]}, {"Citation": "Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology. 1999;117:838\u201347.", "ArticleIdList": ["10500066", "10.1016/S0016-5085(99)70342-2"]}, {"Citation": "Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer. 2008;122:2115\u201324.", "ArticleIdList": ["18172863", "10.1002/ijc.23315"]}, {"Citation": "Reddy BS, Wang CX, Kong A-N, Khor TO, Zheng X, Steele VE, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res. 2006;66:4542\u20136.", "ArticleIdList": ["16618783", "10.1158/0008-5472.CAN-05-4428"]}, {"Citation": "Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001;1:141\u20139.", "ArticleIdList": ["12467231"]}, {"Citation": "Wang G, Cao R, Wang Y, Qian G, Dan HC, Jiang W, et al. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPAR\u03b3 signalling pathway. Sci Rep. 2016;6:35783.", "ArticleIdList": ["27779188", "5078845", "10.1038/srep35783"]}, {"Citation": "Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S, Somanath PR. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer. 2012;12:409.", "ArticleIdList": ["22974127", "3522038", "10.1186/1471-2407-12-409"]}, {"Citation": "Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40:935\u201341.", "ArticleIdList": ["22134829", "10.3892/ijo.2011.1273"]}, {"Citation": "Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL. Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. PLoS\u00a0One. 2013;8: e70442.", "ArticleIdList": ["23936432", "3731278", "10.1371/journal.pone.0070442"]}, {"Citation": "Nooshabadi VT, Khanmohammadi M, Shafei S, Banafshe HR, Malekshahi ZV, Ebrahimi-Barough S, et al. Impact of atorvastatin loaded exosome as an anti-glioblastoma carrier to induce apoptosis of U87 cancer cells in 3D culture model. Biochem Biophys Rep. 2020;23: 100792.", "ArticleIdList": ["32793818", "7408343"]}, {"Citation": "Sheng B, Song Y, Zhang J, Li R, Wang Z, Zhu X. Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy. Am J Transl Res. 2020;12:5252\u201368.", "ArticleIdList": ["33042417", "7540084"]}, {"Citation": "Kim W, Yoon JH, Kim JR, Jang IJ, Bang YJ, Kim YJ, et al. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-\u03b2 inhibitor in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;64:497\u2013507.", "ArticleIdList": ["19096848", "10.1007/s00280-008-0897-1"]}, {"Citation": "Liu PC, Lu G, Deng Y, Wang CD, Su XW, Zhou JY, et al. Inhibition of NF-\u03baB pathway and modulation of MAPK signaling pathways in glioblastoma and implications for lovastatin and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) combination therapy. PLoS\u00a0One. 2017;12: e0171157.", "ArticleIdList": ["28135339", "5279772", "10.1371/journal.pone.0171157"]}, {"Citation": "Wang Z, Zhang L, Wan Z, He Y, Huang H, Xiang H, et al. Atorvastatin and caffeine in combination regulates apoptosis, migration, invasion and tumorspheres of prostate cancer cells. Pathol Oncol Res. 2020;26:209\u201316.", "ArticleIdList": ["29796873", "10.1007/s12253-018-0415-7"]}, {"Citation": "He Y, Huang H, Farischon C, Li D, Du Z, Zhang K, et al. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncol Rep. 2017;37:953\u201360.", "ArticleIdList": ["28075470", "10.3892/or.2017.5353"]}, {"Citation": "Abolghasemi R, Ebrahimi-Barough S, Bahrami N, Aid J. Atorvastatin inhibits viability and migration of MCF7 breast cancer cells. Asian Pac J Cancer Prev. 2022;23:867.", "ArticleIdList": ["35345358", "9360942", "10.31557/APJCP.2022.23.3.867"]}, {"Citation": "Hu MB, Zhang JW, Gao JB, Qi YW, Gao Y, Xu L, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018;42:409\u201315.", "ArticleIdList": ["30300062", "10.1080/01913123.2018.1522406"]}, {"Citation": "Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLoS\u00a0One. 2018;13: e0197422.", "ArticleIdList": ["29763460", "5953490", "10.1371/journal.pone.0197422"]}, {"Citation": "Chen X, Liu Y, Wu J, Huang H, Du Z, Zhang K, et al. Mechanistic study of inhibitory effects of atorvastatin and docetaxel in combination on prostate cancer. Cancer Genom Proteom. 2016;13:151\u201360."}, {"Citation": "Ghalali A, Wiklund F, Zheng H, Stenius U, H\u00f6gberg J. Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis. 2014;35:1547\u201355.", "ArticleIdList": ["24451147", "10.1093/carcin/bgu019"]}, {"Citation": "Ma Q, Gao Y, Xu P, Li K, Xu X, Gao J, et al. Atorvastatin inhibits breast cancer cells by downregulating PTEN/AKT pathway via promoting ras homolog family member B (RhoB). BioMed Res Int. 2019. https://doi.org/10.1155/2019/3235021 .", "ArticleIdList": ["10.1155/2019/3235021", "31976319", "6954475"]}, {"Citation": "Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPAR\u03b3 by Lovastatin and Rosiglitazone. Int J Cancer. 2006;118:2390\u20138.", "ArticleIdList": ["16425225", "10.1002/ijc.21799"]}, {"Citation": "Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh CG. Simvastatin induces derepression of PTEN expression via NF\u03baB to inhibit breast cancer cell growth. Cell Signal. 2010;22:749\u201358.", "ArticleIdList": ["20060890", "2826504", "10.1016/j.cellsig.2009.12.010"]}, {"Citation": "Martinez TA, Zeybek ND, M\u00fcft\u00fco\u011flu S. Evaluation of the cytotoxic and autophagic effects of atorvastatin on MCF-7 breast cancer cells. Balkan Med J. 2018;35:256\u201362.", "ArticleIdList": ["10.4274/balkanmedj.2017.0604"]}, {"Citation": "El-Ashmawy NE, Al-Ashmawy GM, Amr EA, Khedr EG. Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity. Life Sci. 2020;259: 118212.", "ArticleIdList": ["32768581", "10.1016/j.lfs.2020.118212"]}, {"Citation": "Yang Z, Lee M-J, Zhao Y, Yang CS. Metabolism of tocotrienols in animals and synergistic inhibitory actions of tocotrienols with atorvastatin in cancer cells. Genes Nutr. 2012;7:11\u20138.", "ArticleIdList": ["21590436", "10.1007/s12263-011-0233-y"]}, {"Citation": "Yang Z, Xiao H, Jin H, Koo PT, Tsang DJ, Yang CS. Synergistic actions of atorvastatin with \u03b3-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int J Cancer. 2010;126:852\u201363.", "ArticleIdList": ["19626588", "2981082", "10.1002/ijc.24766"]}, {"Citation": "Islam M, Sharma S, Kumar B, Teknos TN. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol. 2013;49:778\u201386.", "ArticleIdList": ["23648017", "4299638", "10.1016/j.oraloncology.2013.04.003"]}, {"Citation": "Toepfer N, Childress C, Parikh A, Rukstalis D, Yang W. Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription. Cancer Biol Ther. 2011;12:691\u20139.", "ArticleIdList": ["21768780", "10.4161/cbt.12.8.15978"]}, {"Citation": "Gurgle HE, Blumenthal DK. Drug therapy for dyslipidemias. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman\u2019s: the pharmacological basis of therapeutics. 13th ed. New York, NY: McGraw-Hill Education; 2017."}, {"Citation": "Derosa G, Sahebkar A, Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol. 2018;233:153\u201361.", "ArticleIdList": ["28098353", "10.1002/jcp.25804"]}, {"Citation": "Hl J, Zhao B-l. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol. 2002;185:172\u20139.", "ArticleIdList": ["10.1006/taap.2002.9538"]}, {"Citation": "Drukala J, Urbanska K, Wilk A, Grabacka M, Wybieralska E, Del Valle L, et al. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPAR\u03b1-mediated inhibition of glioma cell motility in vitro. Mol Cancer. 2010;9:1\u201315.", "ArticleIdList": ["10.1186/1476-4598-9-159"]}, {"Citation": "Grabacka M, Placha W, Plonka PM, Pajak S, Urbanska K, Laidler P, et al. Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res. 2004;296:54\u20138.", "ArticleIdList": ["15278363", "10.1007/s00403-004-0479-y"]}, {"Citation": "Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006;5:1\u201314.", "ArticleIdList": ["10.1186/1476-4598-5-13"]}, {"Citation": "Han D, Zhang J, Wei W, Tao T, Hu Q, Wang Y, et al. Fenofibrate induces G 0/G 1 phase arrest by modulating the PPAR\u03b1/FoxO1/p27 kip pathway in human glioblastoma cells. Tumour Biol. 2015;36:3823\u20139.", "ArticleIdList": ["25566967", "10.1007/s13277-014-3024-4"]}, {"Citation": "Liu J, Ge YY, Zhu HC, Yang X, Cai J, Zhang C, et al. Fenofibrate increases radiosensitivity in head and neck squamous cell carcinoma via inducing G2/M arrest and apoptosis. Asian Pac J Cancer Prev. 2014;15:6649\u201355.", "ArticleIdList": ["25169503", "10.7314/APJCP.2014.15.16.6649"]}, {"Citation": "Majeed Y, Upadhyay R, Alhousseiny S, Taha T, Musthak A, Shaheen Y, et al. Potent and PPAR\u03b1-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. Sci Rep. 2019;9:1\u201314.", "ArticleIdList": ["10.1038/s41598-019-42838-y"]}, {"Citation": "Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator\u2013activated receptor \u03b1 activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res. 2006;12:3028\u201336.", "ArticleIdList": ["16707598", "10.1158/1078-0432.CCR-05-2556"]}, {"Citation": "Yamasaki D, Kawabe N, Nakamura H, Tachibana K, Ishimoto K, Tanaka T, et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPAR\u03b1-independent mechanisms. Eur J Cell Biol. 2011;90:657\u201364.", "ArticleIdList": ["21514001", "10.1016/j.ejcb.2011.02.005"]}, {"Citation": "You B-J, Hour M-J, Chen L-Y, Luo S-C, Hsu P-H, Lee H-Z. Fenofibrate induces human hepatoma Hep3B cells apoptosis and necroptosis through inhibition of thioesterase domain of fatty acid synthase. Sci Rep. 2019;9:1\u201312.", "ArticleIdList": ["10.1038/s41598-019-39778-y"]}, {"Citation": "Kong R, Wang N, Han W, Bao W, Lu J. Fenofibrate exerts antitumor effects in colon cancer via regulation of DNMT1 and CDKN2A. PPAR Res. 2021. https://doi.org/10.1155/2021/6663782 .", "ArticleIdList": ["10.1155/2021/6663782", "33968146", "8081610"]}, {"Citation": "Zhao H, Zhu C, Qin C, Tao T, Li J, Cheng G, et al. Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP. Biochem Biophys Res Commun. 2013;432:320\u20135.", "ArticleIdList": ["23399562", "10.1016/j.bbrc.2013.01.105"]}, {"Citation": "Wybieralska E, Szpak K, G\u00f3recki A, Bonarek P, Mi\u0119kus K, Druka\u0142a J, et al. Fenofibrate attenuates contact-stimulated cell motility and gap junctional coupling in DU-145 human prostate cancer cell populations. Oncol Rep. 2011;26:447\u201353.", "ArticleIdList": ["21617875"]}, {"Citation": "Drukala J, Urbanska K, Wilk A, Grabacka M, Wybieralska E, Del Valle L, et al. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPAR\u03b1 -mediated inhibition of Glioma cell motility in vitro. Mol Cancer. 2010;9:159.", "ArticleIdList": ["20569465", "2912247", "10.1186/1476-4598-9-159"]}, {"Citation": "Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barn\u00e9s CM, Fannon M, et al. PPAR\u03b1 agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci. 2008;105:985\u201390.", "ArticleIdList": ["18199835", "2242705", "10.1073/pnas.0711281105"]}, {"Citation": "Wang MS, Han QS, Jia ZR, Chen CS, Qiao C, Liu QQ, et al. PPAR\u03b1 agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPAR\u03b1/AMPK/AKT/FoxO1 pathway. Acta Pharmacol Sin. 2022;43:167\u201376.", "ArticleIdList": ["33772142", "10.1038/s41401-021-00638-z"]}, {"Citation": "Jan CI, Tsai MH, Chiu CF, Huang YP, Liu CJ, Chang NW. Fenofibrate suppresses oral tumorigenesis via reprogramming metabolic processes: potential drug repurposing for oral cancer. Int J Biol Sci. 2016;12:786.", "ArticleIdList": ["27313493", "4910598", "10.7150/ijbs.13851"]}, {"Citation": "Lian X, Gu J, Gao B, Li Y, Damodaran C, Wei W, et al. Fenofibrate inhibits mTOR-p70S6K signaling and simultaneously induces cell death in human prostate cancer cells. Biochem Biophys Res Commun. 2018;496:70\u20135.", "ArticleIdList": ["29305864", "10.1016/j.bbrc.2017.12.168"]}, {"Citation": "Koltai T. Fenofibrate in cancer: mechanisms involved in anticancer activity. F1000Research. 2015;4:55.", "ArticleIdList": ["10.12688/f1000research.6153.2"]}, {"Citation": "Hu D, Su C, Jiang M, Shen Y, Shi A, Zhao F, et al. Fenofibrate inhibited pancreatic cancer cells proliferation via activation of p53 mediated by upregulation of LncRNA MEG3. Biochem Biophys Res Commun. 2016;471:290\u20135.", "ArticleIdList": ["26850851", "10.1016/j.bbrc.2016.01.169"]}, {"Citation": "Watanabe A, Tanabe A, Maruoka R, Nakamura K, Hatta K, Ono YJ, et al. Fibrates protect against vascular endothelial dysfunction induced by paclitaxel and carboplatin chemotherapy for cancer patients: a pilot study. Int J Clin Oncol. 2015;20:829\u201338.", "ArticleIdList": ["25539886", "10.1007/s10147-014-0779-y"]}, {"Citation": "Goncalves MD, Hwang S-K, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, et al. Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci. 2018;115:E743\u201352.", "ArticleIdList": ["29311302", "5789923", "10.1073/pnas.1714703115"]}, {"Citation": "Fitzgerald JE, Sanyer JL, Schardein JL, Lake RS, McGuire EJ, de la Iglesia FA. Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. J Natl Cancer Inst. 1981;67:1105\u201316.", "ArticleIdList": ["7029098"]}, {"Citation": "Karimi MA, Goudarzi M, Khodayar MJ, Khorsandi L, Mehrzadi S, Fatemi I. Gemfibrozil palliates adriamycin-induced testicular injury in male rats via modulating oxidative, endocrine and inflammatory changes in rats. Tissue Cell. 2023;82: 102037.", "ArticleIdList": ["36863109", "10.1016/j.tice.2023.102037"]}, {"Citation": "Grabacka MM, Wilk A, Antonczyk A, Banks P, Walczyk-Tytko E, Dean M, et al. Fenofibrate induces ketone body production in melanoma and glioblastoma cells. Front Endocrinol. 2016;7:5.", "ArticleIdList": ["10.3389/fendo.2016.00005"]}, {"Citation": "Li T, Zhang Q, Zhang J, Yang G, Shao Z, Luo J, et al. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-\u03baB pathway. BMC Cancer. 2014;14:96.", "ArticleIdList": ["24529079", "4015735", "10.1186/1471-2407-14-96"]}, {"Citation": "Dana N, Haghjooy Javanmard S, Vaseghi G. The effect of fenofibrate, a PPAR\u03b1 activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo. Clin Transl Oncol. 2020;22:486\u201394.", "ArticleIdList": ["31175545", "10.1007/s12094-019-02150-7"]}, {"Citation": "Su T-R, Yu C-C, Chao S-C, Huang C-C, Liao Y-W, Hsieh P-L, et al. Fenofibrate diminishes the self-renewal and metastasis potentials of oral carcinoma stem cells through NF-\u03baB signaling. J Formos Med Assoc. 2022;121:1900\u20137.", "ArticleIdList": ["35151562", "10.1016/j.jfma.2022.01.014"]}, {"Citation": "Tsai SC, Tsai MH, Chiu CF, Lu CC, Kuo SC, Chang NW, et al. AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-\u03ba B pathway. Environ Toxicol. 2016;31:866\u201376.", "ArticleIdList": ["25545733", "10.1002/tox.22097"]}, {"Citation": "Zhang N, Chu ES, Zhang J, Li X, Liang Q, Chen J, et al. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-\u03baB signaling pathway. Oncotarget. 2014;5:8330.", "ArticleIdList": ["25327562", "4226686", "10.18632/oncotarget.2212"]}, {"Citation": "Cornu-Chagnon M-C, Dupont H, Edgar A. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam Appl Toxicol. 1995;26:63\u201374.", "ArticleIdList": ["7657063", "10.1006/faat.1995.1075"]}, {"Citation": "Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-\u03b1 and liver cancer: where do we stand? J Mol Med. 2005;83:774\u201385.", "ArticleIdList": ["15976920", "10.1007/s00109-005-0678-9"]}, {"Citation": "Lian X, Wang G, Zhou H, Zheng Z, Fu Y, Cai L. Anticancer properties of fenofibrate: a repurposing use. J Cancer. 2018;9:1527.", "ArticleIdList": ["29760790", "5950581", "10.7150/jca.24488"]}, {"Citation": "Salvo F, Bazin F, Kostrzewa A, Bandre C, Robinson P, Moore N, et al. Fibrates and risk of cancer in tissues with high PPAR-\u03b1 concentration: a nested case-control study. Drug Saf. 2014;37:361\u20138.", "ArticleIdList": ["24743875", "10.1007/s40264-014-0157-8"]}, {"Citation": "Bonovas S, Nikolopoulos GK, Bagos PG. Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials. PLoS ONE. 2012;7: e45259.", "ArticleIdList": ["23028888", "3446944", "10.1371/journal.pone.0045259"]}, {"Citation": "Wang L-J, Song B-L. Niemann-Pick C1-Like 1 and cholesterol uptake. Biochim Biophys Acta Mol Cell Biol Lipids. 2012;1821:964\u201372.", "ArticleIdList": ["10.1016/j.bbalip.2012.03.004"]}, {"Citation": "Halleck M, Davis H, Kirschmeier P, Levitan D, Snyder R, Treinen K, et al. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology. 2009;258:116\u201330.", "ArticleIdList": ["19428931", "10.1016/j.tox.2009.01.017"]}, {"Citation": "Zheng Y, Yang W, Jia Y, Ji J, Wu L, Feng J, et al. Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction. Front Pharmacol. 2023. https://doi.org/10.3389/fphar.2023.1081980 .", "ArticleIdList": ["10.3389/fphar.2023.1081980", "38273822", "10797415"]}, {"Citation": "Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, et al. Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol. 2009;174:1017\u201326.", "ArticleIdList": ["19179610", "2665761", "10.2353/ajpath.2009.080551"]}, {"Citation": "Allott EH, Masko EM, Freedland AR, Macias E, Pelton K, Solomon KR, et al. Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:196\u2013203.", "ArticleIdList": ["29795142", "6026483", "10.1038/s41391-018-0045-x"]}, {"Citation": "Miura K, Ohnishi H, Morimoto N, Minami S, Ishioka M, Watanabe S, et al. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. Cancer Sci. 2019;110:771\u201383.", "ArticleIdList": ["30520543", "6361611", "10.1111/cas.13902"]}, {"Citation": "Rad F, Davaran S, Babazadeh M, Akbarzadeh A, Pazoki-Toroudi H. Biodegradable electrospun polyester-urethane nanofiber scaffold: codelivery investigation of doxorubicin-ezetimibe and its synergistic effect on prostate cancer cell line. J Nanomater. 2022;2022:8818139. https://doi.org/10.1155/2022/8818139"}, {"Citation": "Yousefnezhad M, Davaran S, Babazadeh M, Akbarzadeh A, Pazoki-Toroudi H. PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: a combination therapy for prostate cancer using a drug repurposing strategy. BioImpacts. 2023. https://doi.org/10.34172/bi.2023.24252 .", "ArticleIdList": ["10.34172/bi.2023.24252", "37431480", "10329752"]}, {"Citation": "Rosseb\u00f8 AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343\u201356.", "ArticleIdList": ["18765433", "10.1056/NEJMoa0804602"]}, {"Citation": "Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet. 2011;377:2181\u201392.", "ArticleIdList": ["10.1016/S0140-6736(11)60739-3"]}, {"Citation": "Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.", "ArticleIdList": ["26039521", "10.1056/NEJMoa1410489"]}, {"Citation": "Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol. 2009;3:138\u201342.", "ArticleIdList": ["21291803", "10.1016/j.jacl.2009.02.005"]}, {"Citation": "Green A, Ramey DR, Emneus M, Iachina M, Stavem K, Bolin K, et al. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Am J Cardiol. 2014;114:1518\u201322.", "ArticleIdList": ["25267716", "10.1016/j.amjcard.2014.08.016"]}, {"Citation": "Kobber\u00f8 Lauridsen B, Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. Int J Epidemiol. 2017;46:1777\u201385.", "ArticleIdList": ["29106532", "10.1093/ije/dyx096"]}, {"Citation": "Nigro ND, Bhadrachari N, Chomchai C. A rat model for studying colonic cancer: effect of cholestyramine on induced tumors. Dis Colon Rectum. 1973;16:438\u201343.", "ArticleIdList": ["4769217", "10.1007/BF02588866"]}, {"Citation": "Nigro ND, Campbell RL, Gantt JS, Lin YN, Singh DV. A comparison of the effects of the hypocholesteremic agents, cholestyramine and candicidin, on the induction of intestinal tumors in rats by azoxymethane. Cancer Res. 1977;37:3198\u2013203.", "ArticleIdList": ["328141"]}, {"Citation": "Melhem MF, Gabriel HF, Eskander ED, Rao KN. Cholestyramine promotes 7,12-dimethylbenzanthracene induced mammary cancer in Wistar rats. Br J Cancer. 1987;56:45\u20138.", "ArticleIdList": ["3113472", "2001672", "10.1038/bjc.1987.150"]}, {"Citation": "Gabriel H, Melhem M, Rao K. Enhancement of DMBA-induced mammary cancer in Wistar rats by unsaturated fat and cholestyramine. In Vivo (Athens, Greece). 1987;1:303\u20137.", "ArticleIdList": ["2979798"]}, {"Citation": "Wedlake L, Thomas K, Lalji A, Anagnostopoulos C, Andreyev HJN. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther. 2009;31:2549\u201358.", "ArticleIdList": ["20109999", "10.1016/j.clinthera.2009.11.027"]}, {"Citation": "Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020;31:1223\u201330.", "ArticleIdList": ["32464281", "10.1016/j.annonc.2020.05.012"]}, {"Citation": "Daugherty JP. Modification of the carcinogenic process in colorectal cancer by endogenous and exogenous factors: effect of colestipol hydrochloride on tumors induced by dimethylhydrazine. Environ Health Perspect. 1983;50:91\u20139.", "ArticleIdList": ["6873034", "1569246", "10.1289/ehp.835091"]}, {"Citation": "Sachatello CR. Colon cancer and cholestyramine. N Engl J Med. 1979;301:1007.", "ArticleIdList": ["492225", "10.1056/NEJM197911013011821"]}, {"Citation": "Naranjo MC, Millan-Linares MC, Montserrat-de la Paz S. Chapter 14\u2014Niacin and hyperlipidemia. In: Patel VB, editor. Molecular nutrition. Academic Press; 2020. p. 263\u201381.", "ArticleIdList": ["10.1016/B978-0-12-811907-5.00008-7"]}, {"Citation": "Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68:92\u2013125.", "ArticleIdList": ["27046161", "10.1016/j.jacc.2016.03.519"]}, {"Citation": "Yaku K, Okabe K, Hikosaka K, Nakagawa T. NAD metabolism in cancer therapeutics. Front Oncol. 2018;8:622.", "ArticleIdList": ["30631755", "6315198", "10.3389/fonc.2018.00622"]}, {"Citation": "Elangovan S, Pathania R, Ramachandran S, Ananth S, Padia RN, Lan L, et al. The Niacin/Butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survivalGPR109A is a tumor suppressor in mammary gland. Cancer Res. 2014;74:1166\u201378.", "ArticleIdList": ["24371223", "10.1158/0008-5472.CAN-13-1451"]}, {"Citation": "Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. ACG. 2005;100:2307\u201314."}, {"Citation": "Kirkland JB. Niacin and carcinogenesis. Nutr Cancer. 2003;46:110\u20138.", "ArticleIdList": ["14690785", "10.1207/S15327914NC4602_02"]}, {"Citation": "Chen AC, Martin AJ, Choy B, Fern\u00e1ndez-Pe\u00f1as P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373:1618\u201326.", "ArticleIdList": ["26488693", "10.1056/NEJMoa1506197"]}, {"Citation": "Park SM, Li T, Wu S, Li WQ, Weinstock M, Qureshi AA, et al. Niacin intake and risk of skin cancer in US women and men. Int J Cancer. 2017;140:2023\u201331.", "ArticleIdList": ["28152570", "5937269", "10.1002/ijc.30630"]}, {"Citation": "Hirakawa N, Okauchi R, Miura Y, Yagasaki K. Anti-invasive activity of niacin and trigonelline against cancer cells. Biosci Biotechnol Biochem. 2005;69:653\u20138.", "ArticleIdList": ["15785001", "10.1271/bbb.69.653"]}, {"Citation": "Lohani M, Dhasmana A, Haque S, Dar SA, Jawed A, Wahid M, et al. Niacin deficiency modulates genes involved in cancer: Are smokers at higher risk? J Cell Biochem. 2019;120:232\u201342.", "ArticleIdList": ["30171725", "10.1002/jcb.27324"]}, {"Citation": "Premkumar VG, Yuvaraj S, Sathish S, Shanthi P, Sachdanandam P. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul Pharmacol. 2008;48:191\u2013201.", "ArticleIdList": ["18407793", "10.1016/j.vph.2008.02.003"]}, {"Citation": "Premkumar VG, Yuvaraj S, Shanthi P, Sachdanandam P. Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy. Br J Nutr. 2008;100:1179\u201382.", "ArticleIdList": ["18377693", "10.1017/S0007114508968276"]}, {"Citation": "Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SGD, Sachdanandam P. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clin Biochem. 2007;40:623\u20138.", "ArticleIdList": ["17425952", "10.1016/j.clinbiochem.2007.02.003"]}, {"Citation": "Sen U, Shenoy PS, Bose B. Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients vitamin C and niacin on colon cancer stem cells (CSCs). Cell Biol Int. 2017;41:1127\u201345.", "ArticleIdList": ["28755485", "10.1002/cbin.10830"]}, {"Citation": "Ying H, Gao L, Liao N, Xu X, Yu W, Hong W. Association between niacin and mortality among patients with cancer in the NHANES retrospective cohort. BMC Cancer. 2022;22:1\u20139.", "ArticleIdList": ["10.1186/s12885-022-10265-4"]}, {"Citation": "Wong CC, Wu J-L, Ji F, Kang W, Bian X, Chen H, et al. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer. Nat Commun. 2022;13:3971.", "ArticleIdList": ["35803966", "9270407", "10.1038/s41467-022-31663-z"]}, {"Citation": "Fang S, Yarmolinsky J, Gill D, Bull CJ, Perks CM, Consortium P, et al. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: a Mendelian randomisation study. PLoS Med. 2023;20: e1003988.", "ArticleIdList": ["36595504", "9810198", "10.1371/journal.pmed.1003988"]}, {"Citation": "Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693\u20138.", "ArticleIdList": ["33177715", "7770056", "10.1038/s41586-020-2911-7"]}, {"Citation": "Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, et al. PCSK9 and cancer: rethinking the link. Biomed Pharmacother. 2021;140: 111758.", "ArticleIdList": ["34058443", "10.1016/j.biopha.2021.111758"]}, {"Citation": "Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia. 2012;14:1122-IN5.", "ArticleIdList": ["10.1593/neo.121252"]}, {"Citation": "Suh JM, Son Y, Yoo J-Y, Goh Y, Seidah NG, Lee S, et al. Proprotein convertase subtilisin/kexin Type 9 is required for Ahnak-mediated metastasis of melanoma into lung epithelial cells. Neoplasia. 2021;23:993\u20131001.", "ArticleIdList": ["34352405", "8350332", "10.1016/j.neo.2021.07.007"]}, {"Citation": "Yang K, Zhu J, Luo H, Yu S, Wang L. Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in ApcMin/+ mice. Int J Immunopathol Pharmacol. 2021;35:20587384211038344.", "ArticleIdList": ["34586888", "8485261", "10.1177/20587384211038345"]}, {"Citation": "Quagliariello V, Bonelli A, Paccone A, Buccolo S, Iovine M, Conforti G, et al. Evolocumab, a PCSK9 inhibitor, co-incubated with doxorubicin and trastuzumab reduces death of cardiomyocytes through reduction of MyD88-NLRP3-NF-kB-mTORC1. Eur Heart J. 2021;42(Suppl 1). https://doi.org/10.1093/eurheartj/ehab724.2839"}, {"Citation": "Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996\u20133003.", "ArticleIdList": ["26330422", "4644253"]}, {"Citation": "Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, et al. Efficacy and safety of alirocumab in Japanese subjects (phase 1 and 2 studies). Am J Cardiol. 2016;118:56\u201363.", "ArticleIdList": ["27184170", "10.1016/j.amjcard.2016.04.011"]}, {"Citation": "Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G, et al. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: a pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Med. 2023;12:16859\u201368.", "ArticleIdList": ["37458138", "10501297", "10.1002/cam4.6310"]}, {"Citation": "Gaba P, O\u2019Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147:1192\u2013203.", "ArticleIdList": ["36779348", "10.1161/CIRCULATIONAHA.122.063399"]}, {"Citation": "Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109\u201319.", "ArticleIdList": ["36620965", "10.1016/S2213-8587(22)00353-9"]}, {"Citation": "Kwon R, Son S. 103P Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer. ESMO Open. 2023;8: 100961.", "ArticleIdList": ["10.1016/j.esmoop.2023.100961"]}, {"Citation": "Saeed ME, Boulos JC, Muecklich SB, Leich E, Chatterjee M, Klauck SM, et al. Disruption of lipid raft microdomains, regulation of CD38, TP53, and MYC signaling, and induction of apoptosis by lomitapide in multiple myeloma cells. Cancer Genom Proteom. 2022;19:540\u201355.", "ArticleIdList": ["10.21873/cgp.20339"]}, {"Citation": "Zuo Q, Liao L, Yao Z-T, Liu Y-P, Wang D-K, Li S-J, et al. Targeting PP2A with lomitapide suppresses colorectal tumorigenesis through the activation of AMPK/Beclin1-mediated autophagy. Cancer Lett. 2021;521:281\u201393.", "ArticleIdList": ["34509534", "10.1016/j.canlet.2021.09.010"]}, {"Citation": "Lee B, Park SJ, Lee S, Lee J, Lee E, Yoo E-S, et al. Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. Cell Death Dis. 2022;13:603.", "ArticleIdList": ["35831271", "9279289", "10.1038/s41419-022-05039-6"]}, {"Citation": "Wang Y, Zhang S, He H, Luo H, Xia Y, Jiang Y, et al. Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. Cell Death Discovery. 2023;9:60.", "ArticleIdList": ["36774350", "9922277", "10.1038/s41420-023-01359-4"]}, {"Citation": "Sen P, Kandasamy T, Ghosh SS. Multi-targeting TACE/ADAM17 and gamma-secretase of notch signalling pathway in TNBC via drug repurposing approach using Lomitapide. Cell Signal. 2023;102: 110529.", "ArticleIdList": ["36423860", "10.1016/j.cellsig.2022.110529"]}, {"Citation": "Larrey D, D\u2019Erasmo L, O\u2019Brien S, Arca M. Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia. Liver Int. 2023;43:413\u201323.", "ArticleIdList": ["36520008", "10.1111/liv.15497"]}, {"Citation": "Freitas RD, Campos MM. Protective effects of omega-3 fatty acids in cancer-related complications. Nutrients. 2019;11:945.", "ArticleIdList": ["31035457", "6566772", "10.3390/nu11050945"]}, {"Citation": "Nabavi SF, Bilotto S, Russo GL, Orhan IE, Habtemariam S, Daglia M, et al. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. Cancer Metastasis Rev. 2015;34:359\u201380.", "ArticleIdList": ["26227583", "10.1007/s10555-015-9572-2"]}, {"Citation": "Dyari HRE, Rawling T, Bourget K, Murray M. Synthetic \u03c9-3 epoxyfatty acids as antiproliferative and pro-apoptotic agents in human breast cancer cells. J Med Chem. 2014;57:7459\u201364.", "ArticleIdList": ["25144895", "10.1021/jm501083y"]}, {"Citation": "Corsetto PA, Montorfano G, Zava S, Jovenitti IE, Cremona A, Berra B, et al. Effects of n-3 PUFAs on breast cancer cells through their incorporation in plasma membrane. Lipids Health Dis. 2011;10:1\u201316.", "ArticleIdList": ["10.1186/1476-511X-10-73"]}, {"Citation": "Xue M, Wang Q, Zhao J, Dong L, Ge Y, Hou L, et al. Docosahexaenoic acid inhibited the Wnt/\u03b2-catenin pathway and suppressed breast cancer cells in vitro and in vivo. J Nutr Biochem. 2014;25:104\u201310.", "ArticleIdList": ["24290517", "10.1016/j.jnutbio.2013.09.008"]}, {"Citation": "Fini L, Piazzi G, Ceccarelli C, Daoud Y, Belluzzi A, Munarini A, et al. Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in ApcMin/+ mice. Clin Cancer Res. 2010;16:5703\u201311.", "ArticleIdList": ["21030497", "3795521", "10.1158/1078-0432.CCR-10-1990"]}, {"Citation": "Cai F, Sorg O, Granci V, Lecumberri E, Miralbell R, Dupertuis YM, et al. Interaction of \u03c9-3 polyunsaturated fatty acids with radiation therapy in two different colorectal cancer cell lines. Clin Nutr. 2014;33:164\u201370.", "ArticleIdList": ["23672803", "10.1016/j.clnu.2013.04.005"]}, {"Citation": "Ceccarelli V, Nocentini G, Billi M, Racanicchi S, Riccardi C, Roberti R, et al. Eicosapentaenoic acid activates RAS/ERK/C/EBP\u03b2 pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. PLoS\u00a0One. 2014;9: e85025.", "ArticleIdList": ["24454781", "3890293", "10.1371/journal.pone.0085025"]}, {"Citation": "Zhuo Z, Zhang L, Mu Q, Lou Y, Gong Z, Shi Y, et al. The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell Dev Biol Anim. 2009;45:69\u201374.", "ArticleIdList": ["19015929", "10.1007/s11626-008-9154-5"]}, {"Citation": "Yao Q-H, Zhang X-C, Fu T, Gu J-Z, Wang L, Wang Y, et al. \u03c9-3 polyunsaturated fatty acids inhibit the proliferation of the lung adenocarcinoma cell line A549 in vitro. Mol Med Report. 2014;9:401\u20136.", "ArticleIdList": ["10.3892/mmr.2013.1829"]}, {"Citation": "Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, et al. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 2011;173:1429\u201339.", "ArticleIdList": ["21518693", "3145396", "10.1093/aje/kwr027"]}, {"Citation": "Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer. 2007;59:14\u201320.", "ArticleIdList": ["17927497", "10.1080/01635580701365068"]}, {"Citation": "Murphy R, Yeung E, Mazurak V, Mourtzakis M. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer. 2011;105:1469\u201373.", "ArticleIdList": ["21970879", "3242518", "10.1038/bjc.2011.391"]}, {"Citation": "Bougnoux P, Hajjaji N, Ferrasson M, Giraudeau B, Couet C, Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer. 2009;101:1978\u201385.", "ArticleIdList": ["19920822", "2779856", "10.1038/sj.bjc.6605441"]}, {"Citation": "Ruscica M, Banach M, Sahebkar A, Corsini A, Sirtori C. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother. 2019;20:791\u2013803.", "ArticleIdList": ["30810432", "10.1080/14656566.2019.1583209"]}, {"Citation": "Zaidi N, Swinnen JV, Smans K. ATP-citrate lyase: a key player in cancer metabolismATP-citrate lyase in cancer metabolism. Cancer Res. 2012;72:3709\u201314.", "ArticleIdList": ["22787121", "10.1158/0008-5472.CAN-11-4112"]}, {"Citation": "Velez BC, Petrella CP, DiSalvo KH, Cheng K, Kravtsov R, Krasniqi D, et al. Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion. Oncol Rep. 2023;49:1\u201311."}, {"Citation": "Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38:1\u201312.", "ArticleIdList": ["10.1186/s13046-019-1391-9"]}, {"Citation": "Litchfield LM, Boehnke K, Brahmachary M, Mur C, Bi C, Stephens JR, et al. Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells. Oncotarget. 2020;11:1478\u201392.", "ArticleIdList": ["32391118", "7197449", "10.18632/oncotarget.27539"]}, {"Citation": "Liu D, Zhang T, Chen X, Zhang B, Wang Y, Xie M, et al. ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY. Cell Death Dis. 2021;12:1113.", "ArticleIdList": ["34839358", "8627506", "10.1038/s41419-021-04410-3"]}, {"Citation": "Qiao C, Huang W, Chen J, Feng W, Zhang T, Wang Y, et al. IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R. Cell Death Dis. 2021;12:564.", "ArticleIdList": ["34075028", "8169856", "10.1038/s41419-021-03833-2"]}, {"Citation": "Ballantyne CM, Banach M, Mancini GJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.", "ArticleIdList": ["29910030", "10.1016/j.atherosclerosis.2018.06.002"]}, {"Citation": "Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330:131\u201340.", "ArticleIdList": ["37354546", "10336623", "10.1001/jama.2023.9696"]}, {"Citation": "Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, et al. Angiopoietin-like proteins in angiogenesis, inflammation and cancer. Int J Mol Sci. 2018;19:431.", "ArticleIdList": ["29389861", "5855653", "10.3390/ijms19020431"]}, {"Citation": "Tang C, Chen E, Peng K, Wang H, Cheng X, Wang Y, et al. Mining the role of angiopoietin-like protein family in gastric cancer and seeking potential therapeutic targets by integrative bioinformatics analysis. Cancer Med. 2020;9:4850\u201363.", "ArticleIdList": ["32410376", "7333835", "10.1002/cam4.3100"]}, {"Citation": "Koyama T, Ogawara K, Kasamatsu A, Okamoto A, Kasama H, Minakawa Y, et al. ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer. Cancer Med. 2015;4:759\u201369.", "ArticleIdList": ["25644496", "4430268", "10.1002/cam4.418"]}, {"Citation": "Wang Y, Yi Y, Pan S, Zhang Y, Fu J, Wu X, et al. Angiopoietin-like protein 3 promotes colorectal cancer progression and liver metastasis partly via the mitogen-activated protein kinase 14 pathway. Mol Carcinog. 2023;62:546\u201360.", "ArticleIdList": ["36692110", "10.1002/mc.23506"]}, {"Citation": "Yu H, Zhang H, Li D, Xue H, Pan C, Zhao S, et al. Effects of ANGPTL3 antisense oligodeoxynucleotides transfection on the cell growths and invasion of human hepatocellular carcinoma cells. Hepatogastroenterology. 2011;58:1742\u20136.", "ArticleIdList": ["21940333", "10.5754/hge10647"]}, {"Citation": "El-Shal AS, Zidan HE, Rashad NM, Wadea FM. Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma. Cytokine. 2017;96:75\u201386.", "ArticleIdList": ["28371666", "10.1016/j.cyto.2017.03.006"]}, {"Citation": "Zhong L, Tang L, He X. Angiopoietin-like 3 (ANGPTL3) drives cell proliferation, migration and angiogenesis in cervical cancer via binding to integrin alpha v beta 3. Bioengineered. 2022;13:2971\u201380.", "ArticleIdList": ["35038961", "8974177", "10.1080/21655979.2021.2024951"]}, {"Citation": "Lupattelli G, Pirro M, Siepi D, Mannarino MR, Roscini AR, Vaudo G, et al. Non-cholesterol sterols in different forms of primary hyperlipemias. Nutr Metab Cardiovasc Dis. 2012;22:231\u20136.", "ArticleIdList": ["20708389", "10.1016/j.numecd.2010.05.010"]}, {"Citation": "Vladimirov S, Gojkovic T, Zeljkovic A, Jelic-Ivanovic Z, Zeljkovic D, Antonic T, et al. Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer? Biochem Pharmacol. 2022;196: 114595.", "ArticleIdList": ["33964280", "10.1016/j.bcp.2021.114595"]}, {"Citation": "Mannarino MR, Ministrini S, Pirro M. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Int Med. 2014;25:592\u20139.", "ArticleIdList": ["10.1016/j.ejim.2014.06.008"]}, {"Citation": "Peter RM, Chou PJ, Shannar A, Patel K, Pan Y, Dave PD, et al. An update on potential molecular biomarkers of dietary phytochemicals targeting lung cancer interception and prevention. Pharma Res. 2023. https://doi.org/10.1007/s11095-023-03595-w"}, {"Citation": "Sun D, Li X, Nie S, Liu J, Wang S. Disorders of cancer metabolism: the therapeutic potential of cannabinoids. Biomed Pharmacother. 2023;157: 113993.", "ArticleIdList": ["36379120", "10.1016/j.biopha.2022.113993"]}, {"Citation": "Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology. 2005;66:1209\u201312.", "ArticleIdList": ["16360444", "10.1016/j.urology.2005.06.075"]}, {"Citation": "Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The lancet. 2002;360:1623\u201330.", "ArticleIdList": ["10.1016/S0140-6736(02)11600-X"]}, {"Citation": "Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, et al. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol. 2017;35:1506.", "ArticleIdList": ["28240967", "5455702", "10.1200/JCO.2016.69.7391"]}, {"Citation": "Lai S-W, Liao K-F, Lai H-C, Muo C-H, Sung F-C, Chen P-C. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol. 2013;28:485\u201392.", "ArticleIdList": ["23681775", "10.1007/s10654-013-9806-y"]}, {"Citation": "Chiu H-F, Ho S-C, Chen C-C, Yang C-Y. Statin use and the risk of liver cancer: a population-based case\u2013control study. ACG. 2011;106:894\u20138."}, {"Citation": "Tsan Y-T, Lee C-H, Ho W-C, Lin M-H, Wang J-D, Chen P-C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31:1514\u201321.", "ArticleIdList": ["23509319", "10.1200/JCO.2012.44.6831"]}, {"Citation": "Tsan Y-T, Lee C-H, Wang J-D, Chen P-C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30:623\u201330.", "ArticleIdList": ["22271485", "10.1200/JCO.2011.36.0917"]}, {"Citation": "Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, Cload P, et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol. 2011;58:530\u20137.", "ArticleIdList": ["21777752", "10.1016/j.jacc.2011.04.015"]}, {"Citation": "Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643\u20137.", "ArticleIdList": ["15578694", "10.1002/ijc.20758"]}, {"Citation": "El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601\u20138.", "ArticleIdList": ["19208359", "10.1053/j.gastro.2009.01.053"]}, {"Citation": "Tseng C-H. Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based study. PLoS\u00a0One. 2014;9: e101553.", "ArticleIdList": ["24991802", "4081573", "10.1371/journal.pone.0101553"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "7", "Day": "31"}, {"Year": "2023", "Month": "10", "Day": "27"}, {"Year": "2023", "Month": "10", "Day": "27"}, {"Year": "2024", "Month": "2", "Day": "2", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "11", "Day": "28", "Hour": "12", "Minute": "41"}, {"Year": "2023", "Month": "11", "Day": "28", "Hour": "11", "Minute": "14"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38015371", "10.1007/s43440-023-00553-6", "10.1007/s43440-023-00553-6"]}}], "PubmedBookArticle": []}